Elidel Sales Fall In Q3 On Fewer U.S. Prescriptions, Novartis Says

Sales of Novartis' eczema treatment Elidel (pimecrolimus) fell 36% to $53 mil. in the third quarter on fewer U.S. prescriptions, Novartis reported Oct. 18